| I-002 Kimberly Adams Physiologically-Based Pharmacokinetic Modeling of Extended-Release MK-2048 Formulations for HIV Pre-Exposure Prophylaxis in Non-Human Primates Wednesday 10:20-11:50 |
| I-009 Magali Amiel Physiologically Based Pharmacokinetic modelling of the Drug-Drug Interaction between Ivacaftor and Lefamulin in Cystic Fibrosis patients Wednesday 10:20-11:50 |
| I-010 Karkhanis Aneesh A PBPK model of 4β-hydroxycholesterol, an endogenous biomarker for hepatic CYP3A activity. Wednesday 10:20-11:50 |
| I-028 Salih Benamara Development of a PBPK model to predict monoclonal antibody pharmacokinetics and bioavailability following subcutaneous administration Wednesday 10:20-11:50 |
| I-051 Zhihai Cao Evaluating Drug Interactions Between Ritonavir and Hydrocodone: Implications From Physiologically Based Pharmacokinetic Simulation Wednesday 10:20-11:50 |
| I-053 Adriana Castiñeiras Population analysis of the in vivo pharmacokinetic characteristics of a letrozole sustained delivery formulation in Beagle dogs Wednesday 10:20-11:50 |
| I-060 Wenjun Chen Physiologically based pharmacokinetic modeling of TLL-018 for prediction of human pharmacokinetics and in vitro-in vivo extrapolation Wednesday 10:20-11:50 |
| I-063 Marylore Chenel Physiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation in the treatment of cryptococcal meningoencephalitis. Wednesday 10:20-11:50 |
| I-069 Léa COMIN Modelling the whole-body pharmacokinetics (WBPK) of radiolabeled glyburide in healthy volunteers Wednesday 10:20-11:50 |
| I-071 Bárbara Costa Pharmacokinetic Simulation Study: Exploring Lamotrigine's Impact Across Diverse Patient Populations Wednesday 10:20-11:50 |
| I-091 Ricardo Diaz de Leon Ortega Modelling and simulation of the effect of a permeability enhancer on the absorption of a poorly permeable compound Wednesday 10:20-11:50 |
| I-093 Aris Dokoumetzidis Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modeling Wednesday 10:20-11:50 |
| I-100 Xiaoqing Fan A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron Wednesday 10:20-11:50 |
| I-107 Denise Feick How can we inform human intestinal permeability with Caco-2 permeability using PK-Sim®? Wednesday 10:20-11:50 |
| I-114 Laura Fuhr Physiologically based pharmacokinetic modeling of amitriptyline and its active metabolite nortriptyline to investigate CYP2D6 and CYP2C19 mediated drug-drug and drug-gene interactions Wednesday 10:20-11:50 |
| II-014 Sandra Grañana Castillo Nintedanib physiologically based pharmacokinetic (PBPK) model to predict drug-drug interactions Wednesday 15:20-16:50 |
| II-024 Jeongmin Ha Physiologically based Pharmacokinetic and Pharmacodynamic modeling of Enzalutamide and N-desmethyl enzalutamide Wednesday 15:20-16:50 |
| II-047 Miao-Chan Huang Application of physiologically-based kinetic (PBK) modeling in revealing the role of the bile-salt efflux pump (BSEP) in bosentan-induced cholestasis Wednesday 15:20-16:50 |
| II-055 Ravi Kumar Jairam Systemic and ocular physiologically based pharmacokinetic models for protein therapeutics in rabbits Wednesday 15:20-16:50 |
| II-057 Masoud Jamei Same Dissolution Profile – Different Virtual Bioequivalence (VBE) Outcome! Input-Dependent Propagation of Between Subject Variability (BSV) in Gut Physiology to Dissolution and VBE Wednesday 15:20-16:50 |
| II-082 Christina Kovar A Physiologically Based Pharmacokinetic Model of Atorvastatin Acid Predicting CYP3A4 and OATP1B Drug–Drug Interactions Wednesday 15:20-16:50 |
| II-088 Jonas Langeraert Small molecule drug absorption in inflammatory bowel disease and current implementation in PBPK models. Wednesday 15:20-16:50 |
| II-089 Emilie Langeskov WB-PBPK-PD Modeling for Pharmacokinetics and Pharmacodynamics of GalNAc-Conjugated siRNAs Wednesday 15:20-16:50 |
| II-111 Helena Loer Unraveling the CYP2D6 Drug-Drug-Gene Interaction Network: A Comprehensive PBPK Analysis of Key Substrates and Inhibitors Wednesday 15:20-16:50 |
| II-112 Ioannis Loisios-Konstantinidis Physiologically based pharmacokinetic modeling and simulations to characterize the effect of cyclodextrins on the exposure of asciminib in lieu of clinical trials Wednesday 15:20-16:50 |
| II-113 Orphélie Lootens Unlocking Diversity: Towards a Comprehensive Framework for Physiologically Based Pharmacokinetic Population Qualification in Sub Saharan Africa Wednesday 15:20-16:50 |
| III-012 Fatima Zahra Marok Parent-Metabolite Physiologically Based Pharmacokinetic Modeling of Mirtazapine during Drug-Drug- and Drug-Gene-Interactions Thursday 09:50-11:20 |
| III-025 Sarang Mishra PBPK modelling based estimation of safe, and effective Molnupiravir doses for pediatric subpopulations against SARS-CoV-2 Thursday 09:50-11:20 |
| III-043 Chen Ning Physiologically based pharmacokinetic modeling and simulation of a promising novel antiplatelet drug vicagrel and its metabolites Thursday 09:50-11:20 |
| III-045 Pär Nordell Predicting in vivo disposition of OATP substrates from in vitro kinetics using mechanistic PBPK modelling Thursday 09:50-11:20 |
| III-050 Marije Otto Characterization of absorption kinetics of oral esketamine in healthy volunteers Thursday 09:50-11:20 |
| III-053 Agustos Cetin Ozbey PBPK modeling based clinical dose adaptation in liver cirrhosis patients for seven CYP and UGT enzyme substrates Thursday 09:50-11:20 |
| III-058 Madison Parrot A Minimal PBPK Model to Predict Biodistribution of Silica Nanoparticles in Mice Thursday 09:50-11:20 |
| III-067 Sara Peribanez A physiologically-based pharmacokinetic model to predict systemic and organ exposure for colorectal cancer drugs in clinical settings Thursday 09:50-11:20 |
| III-085 Javier Reig-López Assessment of bioequivalence outcomes of oral formulations containing racemic ibuprofen through a chiral physiologically-based pharmacokinetic model Thursday 09:50-11:20 |
| III-096 Donnia Robins Elucidating parametric first and second-order effects in PBPK models for special scenarios using a GSA-based approach Thursday 09:50-11:20 |
| III-098 Karine Rodriguez-Fernandez Estimation of a sensitive range of dose-adjusted FaSSIF solubility to predict the food effect on BCS II/IV drugs Thursday 09:50-11:20 |
| III-102 Karen Rowland Yeo Relative impact of CYP2D6 phenotype, physiological changes and hepatic extraction ratio on drug exposure during pregnancy Thursday 09:50-11:20 |
| IV-016 Felix Stader Physiologically based pharmacokinetic modelling to predict the concentration-time profile of an antibody-drug conjugate and hepatic and renal impairment. Thursday 15:00-16:30 |
| IV-061 Daan van Valkengoed Reliability of in vitro data for the mechanistic prediction of brain extracellular fluid pharmacokinetics of P-glycoprotein substrates in vivo; are we scaling correctly? Thursday 15:00-16:30 |
| IV-076 Paul Vrenken Development of a novel open-source Physiology-Based Biopharmaceutics Modelling (PBBM) framework using the Open System Pharmacology suite Thursday 15:00-16:30 |
| IV-083 Haini Wen Translational physiologically based pharmacokinetic modeling to predict human pulmonary kinetics after inhalation Thursday 15:00-16:30 |
| IV-110 Xiaonan Zhang Assessing the Effect of Pneumonia on Tigecycline Lung Exposure Using Physiological-Based Pharmacokinetic Modelling Thursday 15:00-16:30 |
